What is Aidoc?
Established in 2016, Aidoc operates at the intersection of medical diagnostics and machine learning. The company's proprietary aiOS serves as a foundational layer for healthcare systems, continuously analyzing medical data in the background to alert care teams to urgent clinical findings. By operationalizing the unexpected, Aidoc empowers clinicians to prioritize critical cases, thereby optimizing both economic value and clinical efficacy. Its market position is defined by a seamless integration into existing hospital workflows, ensuring that AI-driven intelligence is always active and accessible to frontline medical staff.
How much funding has Aidoc raised?
Aidoc has raised a total of $570M across 7 funding rounds:
Series A
$7M
Series B
$47M
Series C
$66M
Series D
$110M
Debt
$40M
Other Financing Round
$150M
Series E
$150M
Series A (2017): $7M with participation from Magma Ventures, TLV Partners, and Emerge
Series B (2020): $47M, investors not publicly disclosed
Series C (2021): $66M supported by General Catalyst
Series D (2022): $110M featuring CDIB Capital International, Alpha Intelligence Capital, and The TCV
Other Financing Round (2025): $150M backed by SquarePeg, General Catalyst, Hartford HealthCare, Sutter Health, WellSpan Health, Mercy, NVIDIA, and NVentures
Debt (2025): $40M, investors not publicly disclosed
Series E (2026): $150M led by General Catalyst, Softbank Vision Fund, Goldman Sachs, and nVentures
Key Investors in Aidoc
General Catalyst
A venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, including healthcare and enterprise software.
Softbank Vision Fund
A global investment fund that supports founders in building market-leading companies through its extensive ecosystem and capital resources, with a specific focus on the AI sector.
Goldman Sachs
A leading global investment banking and management firm providing strategic advisory and capital to corporations and institutional clients worldwide.
What's next for Aidoc?
With this latest infusion of capital, Aidoc is well-positioned to scale its aiOS platform across broader enterprise-level healthcare networks. The strategic focus will likely center on expanding the diagnostic capabilities of its AI suite and deepening partnerships with major health systems. As the company transitions into its next phase of maturity, the emphasis remains on enhancing the interoperability of its technology, ensuring that clinical teams can navigate complex data environments with greater precision and speed. This investment provides the necessary runway to accelerate product development and solidify Aidoc's footprint in the global digital health market.
See full Aidoc company page
